What is he best known for?
The fields of study he is best known for:
- Enzyme
- Biochemistry
- Organic chemistry
Maurice Petitou spends much of his time researching Heparin, Stereochemistry, Antithrombin, Biochemistry and Oligosaccharide.
He combines subjects such as Anticoagulant, Structure–activity relationship, Pharmacology and Antithrombotic with his study of Heparin.
Maurice Petitou has included themes like Iduronic acid, Sulfation and Tetrasaccharide in his Stereochemistry study.
His Antithrombin research is multidisciplinary, relying on both Total synthesis and Binding site.
His study in the field of Proteases, Binding domain and Molecular model also crosses realms of Idraparinux.
His work carried out in the field of Oligosaccharide brings together such families of science as Residue, Cleavage, Depolymerization and Thrombin.
His most cited work include:
- Structure-activity relationship in heparin : a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity (581 citations)
- The anticoagulant activation of antithrombin by heparin. (551 citations)
- The Unique Antithrombin III Binding Domain of Heparin: A Lead to New Synthetic Antithrombotics (319 citations)
What are the main themes of his work throughout his whole career to date?
Maurice Petitou mainly investigates Heparin, Stereochemistry, Antithrombin, Biochemistry and Thrombin.
His Heparin research includes elements of Biological activity, Structure–activity relationship, Pharmacology and Antithrombotic.
His Stereochemistry research integrates issues from Iduronic acid, Sulfation, Chemical synthesis and Residue.
His research in Antithrombin intersects with topics in Binding domain, Binding site, Anticoagulant, Factor Xa Inhibitor and Conformational change.
The various areas that Maurice Petitou examines in his Biochemistry study include Molecule and Bioavailability.
His Thrombin study combines topics from a wide range of disciplines, such as Coagulation and Ternary complex.
He most often published in these fields:
- Heparin (52.89%)
- Stereochemistry (47.11%)
- Antithrombin (45.45%)
What were the highlights of his more recent work (between 2004-2020)?
- Biochemistry (38.02%)
- Antithrombin (45.45%)
- Heparin (52.89%)
In recent papers he was focusing on the following fields of study:
His primary scientific interests are in Biochemistry, Antithrombin, Heparin, Pharmacology and Oligosaccharide.
His Biochemistry research is multidisciplinary, incorporating perspectives in Cancer and Stem cell.
As a part of the same scientific family, Maurice Petitou mostly works in the field of Antithrombin, focusing on Factor Xa Inhibitor and, on occasion, Antithrombotic, Anesthesia and Antithrombins.
The Heparin study combines topics in areas such as Plasma protein binding and Anti hiv activity.
His study ties his expertise on Stereochemistry together with the subject of Heparan sulfate.
His Stereochemistry research includes themes of Glycoprotein and Glucosamine.
Between 2004 and 2020, his most popular works were:
- Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin (188 citations)
- Fondaparinux, a Synthetic Pentasaccharide: The First in a New Class of Antithrombotic Agents — The Selective Factor Xa Inhibitors (117 citations)
- Molecular modeling of the interaction between heparan sulfate and cellular growth factors: Bringing pieces together (33 citations)
In his most recent research, the most cited papers focused on:
- Enzyme
- Organic chemistry
- Biochemistry
His scientific interests lie mostly in Heparin, Antithrombin, Factor Xa Inhibitor, Fondaparinux Sodium and Biochemistry.
His Heparan sulfate study in the realm of Heparin interacts with subjects such as Population.
The concepts of his Heparan sulfate study are interwoven with issues in Docking, Stereochemistry, Fibroblast growth factor, Random hexamer and Chemical synthesis.
His work deals with themes such as Pharmacokinetics, Virology, Potency, Subcutaneous injection and Biological activity, which intersect with Antithrombin.
His Factor Xa Inhibitor research is multidisciplinary, incorporating elements of Discovery and development of direct thrombin inhibitors, Thrombin and Antithrombins.
His study in the fields of Plasma protein binding, In vitro, Oligosaccharide and Structure–activity relationship under the domain of Biochemistry overlaps with other disciplines such as Molecular mimicry.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
